Parizad Torabi-Parizi, M.D.


Laboratory of Basic and Translational Immunology


NIHBC 10 – Clinical Center BG RM 2C138
10 Center Drive
Bethesda, MD 20892
United States


Research Topics

Dr. Torabi-Parizi’s program focuses on understanding innate immune cell and effector T cell behavior in peripheral tissues, mechanisms regulating such behavior, and possible interventions that might modulate these responses to improve host outcomes in the context of critical illness, with a particular emphasis on checkpoint pathways. Her current work includes establishing rodent models of sepsis and acute lung injury that allow for the evaluation of molecular mechanisms of host injury and the introduction of therapeutic interventions to alter outcomes.


Dr. Parizad Torabi-Parizi earned her undergraduate degree in Chemistry and degree in Medicine from Emory University. She completed her internship and residency training in Internal Medicine at the Johns Hopkins Hospital Osler Training Program. She then completed her fellowship training in Critical Care Medicine at the NIH and is now a Tenure-Track Investigator in the NHLBI.

Selected Publications

  1. Busch LM, Sun J, Cui X, Eichacker PQ, Torabi-Parizi P. Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Med Exp. 2020;8(1):7.
  2. Busch LM, Sun J, Eichacker PQ, Torabi-Parizi P. Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review. Crit Care Med. 2020;48(9):1365-1374.
  3. Curran CS, Bolig T, Torabi-Parizi P. Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection. Am J Respir Crit Care Med. 2018;197(6):708-727.
  4. Curran CS, Busch LM, Li Y, Xizhong C, Sun J, Eichacker PQ, Torabi-Parizi P. Anti-PD-L1 therapy does not improve survival in a murine model of lethal Staphyloccocus aureus pneumonia. J Infect Dis. 2021.

Related Scientific Focus Areas

This page was last updated on Tuesday, April 23, 2024